Search

Displaying results 7241 - 7250 of 8696 in total
  1. Drug

    IBIO-100

    go.drugbank.com/drugs/DB18233
    Experimental

    IBIO-100 is a high molecular weight multimer of E3-Fc, an endostatin C-terminus and IgG1-Fc fusion protein.

  2. Drug

    VOR33

    go.drugbank.com/drugs/DB18624
    Investigational

    VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 protein.

  3. Drug

    ECT-001 expanded cord blood

    go.drugbank.com/drugs/DB21745
    Investigational

    [L52013] It is being investigated in hematopoietic cell transplantation as ECT-001 expanded cord blood can demonstrate enhanced stem cell proliferation and engraftment compared to untreated UBCs.

  4. Drug

    Elsamitrucin

    go.drugbank.com/drugs/DB05129
    Investigational

    The cytostatic agent Elsamitrucin is a new fermentation product active in a variety of in vivo tumor models of murine and human origin. (PMID: 8150873)

  5. Drug

    Bupranolol

    go.drugbank.com/drugs/DB08808
    Experimental

    Bupranolol is a non-selective beta blocker with potency similar to propanolol. It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  6. Drug

    Atrazine

    go.drugbank.com/drugs/DB07392
    Experimental

    Acutely poisoned sheep and cattle may show muscular spasms, fasciculations, stiff gait, increased respiratory rates, adrenal degeneration, and congestion of the lungs, liver, and kidneys.

  7. Drug

    TBC-3711

    go.drugbank.com/drugs/DB05407
    Investigational

    TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.

    Categories: Endothelin Receptor Antagonists, Endothelin A Receptor Antagonists
  8. Drug

    SRP-9005

    go.drugbank.com/drugs/DB17958
    Investigational

    Developed by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of Limb-girdle muscular dystrophy (LGMD) type 2C/R5.[A260142]

  9. Drug

    Navamepent

    go.drugbank.com/drugs/DB21096
    Investigational

    Navamepent is under investigation in clinical trial NCT02329743 (Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery).

    Categories: P-glycoprotein inhibitors
  10. Drug

    Enprostil

    go.drugbank.com/drugs/DB13824
    Experimental

    Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)